J9037 belantamab mafodotin HCPCS Reimbursement | OpenPayer

Summary & Overview

HCPCS J9037: Injection, belantamab mafodotin-blmf, 0.5 mg

HCPCS Level II code J9037 denotes injection units of belantamab mafodotin-blmf, an oncology biologic billed per 0.5 mg. This code matters nationally as it standardizes reporting for a specialty infusion therapy used in cancer care, affecting hospital outpatient, infusion center, and physician office billing. Accurate coding supports clinical documentation, payer reimbursement workflows, and national utilization tracking for high-cost oncology agents.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage considerations across major commercial plans and Medicare, common billing practices for unit-based biologic J-codes, and what to expect in claims submission for infusion sites. The publication summarizes benchmarks where available, highlights relevant policy updates that affect coding and payment, and provides clinical context for how the drug is typically administered.

The piece is designed for billing managers, revenue cycle professionals, and clinical leaders who need concise guidance on how HCPCS Level II code J9037 is used operationally and reported to major payers. Data not available in the input will be noted when necessary in detailed sections.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ9037HCPCS Level IIbelantamab mafodotinoncologyinjectableinfusiondrug-codingoutpatient-billing

Billing Code Overview

HCPCS Level II code J9037 represents the medication belantamab mafodotin-blmf, billed per 0.5 mg unit for injection. This code covers administration of the specified oncology drug formulation.

Service type: Injectable oncology medication
Typical site of service: Hospital outpatient departments, physician offices, and infusion centers where parenteral oncology therapies are delivered.

Clinical & Coding Specifications

Clinical Context

A typical patient is a 65-year-old with relapsed or refractory multiple myeloma who has exhausted at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The patient presents to an outpatient oncology infusion center for administration of J9037 (belantamab mafodotin-blmf) as a scheduled intravenous or ophthalmic-precaution infusion per institutional protocol. Pre-infusion workflow includes verification of diagnosis and prior therapies, review of current medications and allergies, baseline laboratory tests (CBC, CMP), and an ophthalmology assessment because of corneal toxicity risk. The infusion nurse confirms weight-based dosing and prepares the appropriate number of 0.5 mg vial(s) of J9037, documents lot numbers and expiration dates, and performs standard chemotherapy safety checks.

During the visit, vital signs are obtained and an informed consent/therapy counseling discussion is recorded. The medication is administered per facility policy with monitoring for infusion reactions and immediate adverse events; emergency medications and resuscitation equipment are available. Post-infusion monitoring includes observation for infusion-related reaction, documentation of administered dose and any administered premedications, and scheduling of follow-up ophthalmology evaluations and subsequent dosing visits. Billing for J9037 is performed per vial unit (0.5 mg) with appropriate CPT codes for infusion services and applicable modifier reporting for payer requirements.

Coding Specifications

Modifier

Related Codes

HCPCS-J9248-MELPHALAN-INJECTION-1MG

HCPCS J9248: Melphalan Injection, 1 mg

HCPCS-J9303-PANITUMUMAB-INJECTION-10MG

HCPCS Level II J9303: Panitumumab Injection, 10 mg

HCPCS-J9600-PORFIMER-SODIUM-75MG-INJECTION

HCPCS J9600: Injection, Porfimer Sodium 75 mg

HCPCS-J9278-CARBOPLATIN-INJECTION-1MG

HCPCS Level II J9278: Carboplatin (avyxa) Injection, 1 mg

HCPCS-J9153-LIPOSOMAL-DAUNORUBICIN-CYTARABINE-INJECTION

HCPCS J9153: Liposomal Daunorubicin and Cytarabine Injection

HCPCS-J9322-PEMETREXED-BLUEPOINT-10MG-INJECTION

HCPCS J9322: Pemetrexed (bluepoint) Injection, 10 mg

HCPCS-J9329-TISLELIZUMAB-INJECTION-1MG

HCPCS Level II J9329: Injection of tislelizumab-jsgr, 1 mg

HCPCS-J9074-CYCLOPHOSPHAMIDE-INJECTION-5MG

HCPCS J9074: Cyclophosphamide Injection, 5 mg

HCPCS-J9181-ETOPOSIDE-10MG-INJECTION

HCPCS J9181: Injection, etoposide, 10 mg

HCPCS-J9260-METHOTREXATE-INJECTION-50MG

HCPCS J9260: Injection, Methotrexate Sodium, 50 mg

Showing 1–10 of 227

`11`	Administrative or documentation material included	When the service includes routine documentation without a separate billable professional component, used per payer guidance if applicable.
`22`	Increased procedural services	When substantially greater work than typical is required (e.g., extended counseling due to complex toxicity management). Use only with documentation supporting increased work.
`23`	Unusual anesthesia	Rarely used with `J9037`; only applicable if unusual anesthesia unrelated to chemotherapy administration is provided and billed.
`52`	Reduced services	When less than the full service was performed (for example, partial vial wasted and not administered). Use with clear documentation.
`53`	Discontinued procedure	When the infusion is started but discontinued due to patient intolerance or adverse event before completion.
`54`	Surgical care only	Not typically applicable; included when a separate surgical service is billed on the same day by another provider.
`55`	Postoperative management only	Not typically applicable to drug administration; used if only postoperative care is provided by the billing provider.
`62`	Two surgeons	Not generally applicable; used only if two surgeons are involved in a same-day qualifying procedure.
`AS`	Left on table or Ambulatory Surgery modifier (payer-specific)	Use per payer policy when facility or payer requires designation for ambulatory procedures when applicable to the infusion setting.
`CO`	Worker's Compensation or related payer	When the claim is related to an occupational injury covered by a workers' compensation carrier.
`CQ`	Service furnished under a CMS Innovation Center model	When the service is provided under a designated CMS innovation payment model.
`QK`	Medical direction of two, three, or four concurrent anesthesia procedures	Not typically applicable to infusion therapy; included when anesthesia billing rules apply.
`QX`	CRNA service with medical direction by a physician	Only used if anesthesia is billed with these supervision characteristics.
`QY`	Anesthesiologist medically directs one CRNA	Only used if anesthesia services meet these conditions.
`SH`	Hospital-based split/shared service	When split/shared E/M or other services are furnished in a hospital and meet payer criteria for practitioner attribution.

Taxonomy Code	Specialty	Notes
`207RC0000X`	Hematology & Oncology	Medical oncologists and hematologist-oncologists who prescribe and manage belantamab mafodotin therapy.
`2084P0200X`	Medical Oncology	Oncologists providing systemic therapy administration and treatment planning.
`363L00000X`	Oncology Nursing	Infusion and chemotherapy-certified registered nurses providing drug preparation, administration, and monitoring.
`207K00000X`	Ophthalmology	Ophthalmologists performing baseline and follow-up corneal exams and slit-lamp evaluations due to ocular toxicity risk.
`261QM0600X`	Clinical Pharmacology	Oncology pharmacists involved in dosing calculations, drug preparation, and medication safety checks.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C90.00`	Multiple myeloma not having achieved remission	Primary diagnosis indicating active multiple myeloma eligible for belantamab mafodotin in relapsed/refractory settings.
`C90.01`	Multiple myeloma in remission	May be used for patients with residual disease surveillance or maintenance considerations when therapy is indicated.
`C90.02`	Multiple myeloma in relapse	Directly relevant for patients receiving `J9037` for relapsed disease after prior therapies.
`D61.0`	Drug-induced aplastic anemia	Relevant as a potential severe hematologic toxicity requiring monitoring and may influence dosing decisions.
`H18.89`	Other corneal deformities	Used to capture existing corneal conditions that may impact baseline ophthalmic assessment before `J9037` treatment.
`H57.10`	Unspecified disorder of eye and adnexa, unspecified eye	Used for non-specific ocular findings that require monitoring during therapy due to corneal toxicity risk.
`Z79.899`	Other long term (current) drug therapy	May be used to indicate ongoing systemic anticancer therapy including belantamab mafodotin.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Commonly billed for the initial 30–60 minute infusion session when `J9037` is administered intravenously.
`96415`	Chemotherapy administration, intravenous infusion technique; each additional hour	Billed when infusion time for `J9037` exceeds the initial unit and requires additional billed hours.
`96417`	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion of a new drug, up to 1 hour	Used when multiple sequential infusions are administered the same day and `J9037` is one of the agents.
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal antineoplastic	Used if an alternative route were applicable; rarely used for `J9037` which is typically intravenous.
`99212`	Office or other outpatient visit for the evaluation and management of an established patient, low complexity	Billed for brief E/M visits related to treatment planning or toxicity assessment on the day of infusion when applicable.
`99070`	Supplies and materials (except spectacles), non-covered items used during patient care	May be used for billable single-use supplies associated with infusion that are not included in the administration code.

Note: If facility bills separately, institutional revenue codes and HCPCS J-code unit reporting are required for accurate reimbursement. Documentation should support the relationship between the CPT administration codes and the J9037 drug administration.